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Thomas CM, Yong QC, Rosa RM, Seqqat R, Gopal S, Casarini
DE, Jones WK, Gupta S, Baker KM, Kumar R. Cardiac-specific
suppression of NF-B signaling prevents diabetic cardiomyopathy via
inhibition of the renin-angiotensin system. Am J Physiol Heart Circ
Physiol 307: H1036–H1045, 2014. First published August 1, 2014;
doi:10.1152/ajpheart.00340.2014.—Activation of NF-B signaling in
the heart may be protective or deleterious depending on the patho-
logical context. In diabetes, the role of NF-B in cardiac dysfunction
has been investigated using pharmacological approaches that have a
limitation of being nonspecific. Furthermore, the specific cellular
pathways by which NF-B modulates heart function in diabetes have
not been identified. To address these questions, we used a transgenic
mouse line expressing mutated IB- in the heart (3M mice), which
prevented activation of canonical NF-B signaling. Diabetes was
developed by streptozotocin injections in wild-type (WT) and 3M
mice. Diabetic WT mice developed systolic and diastolic cardiac
dysfunction by the 12th week, as measured by echocardiography. In
contrast, cardiac function was preserved in 3M mice up to 24 wk of
diabetes. Diabetes induced an elevation in cardiac oxidative stress in
diabetic WT mice but not 3M mice compared with nondiabetic control
mice. In diabetic WT mice, an increase in the phospholamban/
sarco(endo)plasmic reticulum Ca2-ATPase 2 ratio and decrease in
ryanodine receptor expression were observed, whereas diabetic 3M
mice showed an opposite effect on these parameters of Ca2 handling.
Significantly, renin-angiotensin system activity was suppressed in
diabetic 3M mice compared with an increase in WT animals. In
conclusion, these results demonstrate that inhibition of NF-B signal-
ing in the heart prevents diabetes-induced cardiac dysfunction through
preserved Ca2 handling and inhibition of the cardiac renin-angio-
tensin system.
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NF-B SIGNALING has a central role in cardiac pathophysiology
(10). NF-B regulates the expression of several cellular path-
ways that are important in cardiac development as well as
postnatal function. In a pathological context, NF-B activation
has been described in cardiac hypertrophy, ischemia-reperfu-
sion injury, myocardial infarction, heart failure, and diabetic
cardiomyopathy (18, 23). Given the multiple roles of NF-B in
different tissues and disease conditions, questions have been
raised as to whether its activation is protective or detrimental
for heart function in disease states (8). A generally accepted
view is that acute activation of NF-B, such as in precondi-
tioning, is required for cardioprotection, whereas chronic acti-
vation leads to heart failure. The lack of consensus among
different studies is likely due to differences in components of
NF-B signaling investigated and the cell type and patholog-
ical conditions studied (18).
Diabetes is a condition of chronic inflammation, and pro-
longed activation of NF-B has been reported in the diabetic
heart. Cardioprotective effects of a pharmacological agent,
pyrrolidine dithiocarbamate, which are associated with reduced
NF-B activity in the diabetic heart, have been reported (26).
Since pyrrolidine dithiocarbamate also reduces oxidative
stress, it is not clear whether the protection provided by this
compound comes from NF-B inhibition or an attenuation of
oxidative stress. Diabetes also increases the activity of the
cardiac renin-angiotensin system (RAS). Significantly, ANG
II, the bioactive peptide of the RAS, has been reported to
stimulate NF-B activity in several cell types (3, 28, 33, 34,
45). Clinical and experimental studies have shown cardiopro-
tective effects of RAS inhibition in diabetes, which might
partly be due to a reduction in NF-B-mediated inflammation
(12, 37, 47). Thus, evidence exists, albeit indirect, to suggest
the involvement of NF-B in the development of diabetic
cardiomyopathy and heart failure. However, a direct causative
role of NF-B in diabetes-induced cardiac pathology and
putative downstream cellular pathways has not been estab-
lished.
The NF-B signaling pathway is a multicomponent system
with diverse mechanisms of activation (18). The most common
mechanism is the canonical pathway, in which a heterodimer
of p65 and p50 subunits is held in the cytoplasm in an inactive
state by the IB -subunit. Phosphorylation of the latter, as a
result of the appropriate stimuli, leads to degradation and
translocation of the heterodimer to the nucleus. Approaches
using overexpression, deletion, or mutations of the above
subunits in transgenic animals have been used to study the role
of NF-B in various pathophysiological states but not in
diabetic cardiomyopathy (18, 27).
In this study, we used a cardiac-specific transgenic mouse
line that overexpresses IB- protein with a triple mutation
(3M) to prevent its phosphorylation (5). 3M mice have been
well characterized in several studies and reported to have a
normal phenotype with lack of NF-B activation in the heart in
several pathological states and in response to proinflammatory
cytokines (5, 20, 48). We tested the hypothesis that suppression
of NF-B in the heart would protect these animals from
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developing diabetes-induced cardiac dysfunction. Further-
more, we tested whether the lack of NF-B activation attenu-
ates the cardiac RAS, thereby providing a mechanistic expla-
nation of its protective effects.
MATERIALS AND METHODS
Animals. All animal protocols were approved by the Institutional
Animal Care and Use Committee and conformed with National
Institutes of Health guidelines. The generation of 3M mice has
been previously described (5). These mice have been back crossed
to C57bl/6 mice for more than five generations; therefore, C57bl/6J
mice (The Jackson Laboratory, Bar Harbor, ME) were used as
wild-type (WT) mice for comparison. Twelve-week-old male WT
and 3M mice were randomized into control and diabetic groups.
Animals in the diabetic group were injected with streptozotocin (STZ;
50 mg·kg1·day1, Zanosar) intraperitoneally for 5 consecutive days,
whereas animals in the control group received vehicle (0.1 M sodium
citrate buffer, pH 4.5). This multiple low-dose STZ regimen does not
produce nonspecific toxicity, and we did not observe any mortality in
WT and 3M animals (11). After 2 wk, mice with a blood glucose
value of 250 mg/dl were considered diabetic. Heart function was
measured by echocardiography, which was performed every 4 wk
from the beginning of diabetes (0 wk) until the end of the study (24
wk). At 24 wk, animals were anesthetized with isoflurane/O2 (2%/
2%), and hearts collected for further analysis.
Echocardiographic measurements. Transthoracic echocardiogra-
phy was performed using a VisualSonics Vevo 2100 with a 35-MHz
probe, as previously described (37). Briefly, mice were anesthetized
with 3–5% isoflurane (with 2% O2), which was reduced to 1.5% to
maintain heart rate in the range of 400–500 beats/min. The heart was
imaged in the two-dimensional, short-axis, and four-chamber view to
measure multiple parameters of systolic and diastolic function.
Urine collection and albumin-to-creatinine ratio. Mice were indi-
vidually housed in metabolic cages (Techniplast) for 24 h with free
access to food and water. Excreted urine was collected over a 24-h
period, and volume was measured. Urinary albumin excretion was
determined using the albumin-to-creatinine ratio. Urinary albumin and
creatinine were measured using a commercially available Albuwell M
and creatinine companion kit, respectively, according to the manufac-
turer’s instructions (Exocell).
Real-time PCR. Gene expression of -myosin heavy chain (MHC),
-MHC, atrial natriuretic peptide (ANP), brain natriuretic peptide
(BNP), ryanodine receptor 2 (Ryr2), angiotensinogen (AGT), and
renin was determined using TaqMan assays (Applied Biosystems), as
previously described (47). Data were normalized to 18S mRNA. In
the case of renin and AGT, WT and 3M samples were analyzed
separately after a gap of time, resulting in the change of reagents. To
allow baseline comparison, we reanalyzed WT and 3M samples from
control animals together.
Western blot analysis. Protein expression was assessed with the
standard Western immunoblot technique. Briefly, hearts were lysed in
ice-cold lysis buffer (Cell Signaling) supplemented with protease and
phosphatase inhibitor cocktails (Roche Applied Science). Equal
amounts of cell lysate (60 g protein) were separated on SDS-
polyacrylamide gels and transferred to nitrocellulose membranes.
Blots were probed with antibodies for AGT (IBL-America), sarco(endo)
plasmic reticulum Ca2-ATPase 2a (SERCA2; Santa Cruz Biotech-
nology), and phospholamban (PLB; Thermo Scientific). Equal protein
loading was confirmed by -actin levels. Protein bands were detected
using secondary antibodies labeled with infrared dye 680/800 and an
enhanced Odyssey Infrared Imaging System (LI-COR, Biosciences).
Samples from control and diabetic animals were run on the same blot,
resulting in WT and 3M samples being analyzed separately. In the
case of SERCA2 and PLB, a common sample was run along all blots
to correct for interexperimental variation and to allow comparison. In
the case of AGT, we reanalyzed WT and 3M control samples together
on the same gel to allow baseline comparison.
ROS staining. Hearts were fixed in 4% paraformaldehyde and
frozen in OCT compound (Tissue-Tek). Frozen sections (20 m) were
incubated with 10 M dihydroethidium (DHE; Sigma-Aldrich) at
37°C for 30 min in a humidified chamber in the dark. Fluorescent
images (60) were obtained with a Leica TCS SP5X confocal
microscope and analyzed using ImageJ. DHE fluorescence was quan-
tified by dividing the integrated density of the fluorescent staining by
the area for 10 fields/heart (5 hearts/group).
Immunofluorescence staining. Heart sections (5 m) were fixed
with 4% formaldehyde and permeabilized using 0.1–0.3% Triton
X-100. After being blocked, sections were incubated with anti-ANG
II (Bachem, 1:500) and anti-p65 (Cell Signaling, 1:50) antibodies
followed by an incubation with the respective secondary antibodies
(1:500). The specificity of staining was determined using secondary
antibody alone. Sections were costained with phalloidin (1:100),
4=,6-diamidino-2-phenylindole, and/or wheat germ agglutinin to visu-
alize the cytoplasm, nuclei, and cell boundaries, respectively. Images
(60) were acquired with a confocal fluorescence microscope (Leica
TCS SP5X). Cardiac myocyte area and fluorescence intensities were
determined using ImageJ.
Statistical analysis. This study was designed to test the hypothesis
that there is no difference in cardiac function and other parameters
between diabetic and nondiabetic 3M mice. Two-way ANOVA with
a Fisher’s least-significant difference post hoc test or Student’s t-test
(Fig. 7) were used for statistical analysis (GraphPad Prism). P values
of 	0.05 were considered statistically significant.
RESULTS
NF-B signaling may produce protective or deleterious
effects in the heart depending on the pathological condition
(18, 27). To investigate its role in diabetic cardiomyopathy, we
used 3M mice in which NF-B canonical signaling is sup-
pressed in the heart in response to multiple pathological stimuli
(5, 20, 48).
Induction of diabetes and cardiac morphology. Both WT
and 3M mice developed robust, sustained, and equivalent
hyperglycemia (Fig. 1A). After 24 wk of diabetes, the heart
weight-to-tibia length ratio, cardiac myocyte size, and left
ventricular posterior wall thickness were not significantly af-
fected in WT or 3M mice compared with their respective
nondiabetic controls (Fig. 1, B–H). However, 3M mice had
significantly increased baseline values for these morphological
parameters compared with WT mice.
Cardiac function was preserved in 3M mice. Echocardiog-
raphy was used to measure cardiac systolic and diastolic
function every 4 wk after the development of diabetes (only 0-,
12-, and 24-wk data are shown). After 12 wk, a significant
reduction in the ratio of mitral valve flow velocities and an
increase in the isovolumic relaxation time, both parameters of
diastolic dysfunction, were evident in diabetic WT mice (Fig. 2, A
and B). Systolic function, as measured by ejection fraction and
fractional shortening, was also reduced in WT mice beginning
at 12 wk of diabetes (Fig. 2, C and D). Cardiac function further
declined with the duration of diabetes, until the last study point
of 24 wk. However, 3M mice did not show any signs of cardiac
dysfunction through the end of the study (Fig. 2, A–D). There
were no significant differences in baseline (0 wk, control) heart
function between WT and 3M mice except for isovolumic
relaxation time, which appeared to be an artifact considering
the values at other time points.
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Molecular markers of cardiac function are preserved in 3M
mice. To confirm echocardiographic measurements of cardiac
function, we measured the expression of -MHC, -MHC,
ANP, and BNP in the hearts of WT and 3M mice (Fig. 3).
Expression of -MHC was significantly reduced, whereas that
of other markers was increased in diabetic WT animals com-
pared with nondiabetic control animals. A 2.5-fold increase in
the expression of BNP in diabetic WT animals compared with
control animals did not reach statistical significance upon
multiple comparison, due to the large baseline difference
between WT and 3M animals (Fig. 3E). In 3M diabetic mice,
other than -MHC (and, thus, the -MHC-to--MHC ratio),
the expression of these pathological markers did not change
significantly, confirming that diabetes did not induce cardiac
dysfunction in these animals.
The NF-b p65 subunit does not show increased transloca-
tion to the nucleus in diabetic 3M mice. Expression of mutated
IB- in 3M mice prevents the translocation of the p65:p50
dimer to the nucleus and NF-B activation in the heart under
different pathological conditions (5). To confirm that in diabe-
tes there is no enhanced NF-B activation in 3M mice, we
quantified the number of nuclei in the heart that were positive
for p65 immunostaining (Fig. 4, A–E). WT mice had increased
numbers of p65-positive nuclei in diabetic mice compared with
control mice, whereas no increase was observed in diabetic 3M
mice, which was consistent with previous reports (5, 20, 48) of
a lack of NF-B activation in these transgenic mice.
3M mice are protected from diabetes-induced oxidative
stress. We measured oxidative stress in the heart by DHE
staining. Diabetic WT mice had a significant increase in ROS
staining, which was not observed in 3M mice compared with
their respective nondiabetic controls (Fig. 4, F–J). Basal oxi-
dative stress levels were higher in control 3M mice compared
with control WT mice, the reason for which was not clear.
Renal function is not preserved in diabetic 3M mice. Since
3M mice express mutated IB- in a cardiac-specific manner,
the protection provided by NF-B inhibition should be re-
stricted to the heart. To confirm that 3M mice are not protected
from diabetes-induced renal impairment, we evaluated renal
function in these animals by determining the 24-h urine vol-
ume, albumin-to-creatinine ratio, and 24-h albumin excretion.
These parameters were similarly increased in both diabetic WT
and 3M mice compared with their respective nondiabetic
controls, suggesting that renal function was not preserved in
3M mice after hyperglycemia (Fig. 5). However, the difference
in urinary volume and albumin-to-creatinine ratio between
control and diabetic 3M mice did not reach statistical signifi-
cance due to the large variation in these mice.
Ca2-handling proteins in cardiac myocytes of 3M mice are
preserved in diabetes. Cardiac dysfunction in diabetes is asso-
ciated with detrimental changes in expression of the sarcoplas-
mic reticulum Ca2 uptake pump SERCA2 and its inhibitory
protein PLB in cardiac myocytes (15, 36). We determined
whether these changes were prevented in 3M mice in response
to diabetes. SERCA2 expression was reduced in diabetic WT
mice, without any change in PLB expression, resulting in a
significantly increased PLB-to-SERCA2 ratio, which is an
important indicator of inefficient Ca2 uptake to the sarcoplas-
mic reticulum from the cytosol (Fig. 6, A–C). Significantly,
SERCA2 expression was preserved and PLB expression was
reduced in diabetic 3M mice, thereby reducing the PLB-to-
SERCA2 ratio. We also measured gene expression of Ryr2,
which mediates the release of Ca2 from the sarcoplasmic
reticulum to the cytosol. Ryr2 expression was significantly
Fig. 1. Blood glucose and heart morphology parameters after 24 wk of diabetes. Twelve-week-old male C57BL6/J mice [wild-type (WT) mice] and
cardiac-specific transgenic mice expressing mutated IB- (3M mice) were injected with either 0.1 M citrate buffer (pH 4.5, control) or streptozotocin (STZ;
50 mg/kg) for 5 days. A: blood glucose levels after 24 wk of diabetes in control and diabetic (STZ) WT and 3M mice. B–D: parameters of cardiac morphology
in control and diabetic WT and 3M mice. HW/TL, heart weight-to-tibia length ratio; AU, arbitrary units; LVPWd, left ventricular posterior wall thickness.
E–H: confocal images (60) of immunostaining of heart sections with phalloidin (red), wheat germ agglutinin (WGA; green), and 4=,6-diamidino-2-phenylindole
(DAPI; blue) to demonstrate cardiac morphology in control and diabetic WT and 3M mice. The myocyte size plotted in C was calculated from these images using
ImageJ. Values presented in bar charts are means 
 SE; n  5–7. *P 	 0.05 vs. respective control mice; #P 	 0.05 vs. control WT mice.
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downregulated in WT mice and upregulated in 3M mice in
response to hyperglycemia (Fig. 6D). 3M mice had signifi-
cantly higher baseline expression of SERCA2 and lower ex-
pression of Ryr2 compared with WT mice (Fig. 6, A and D).
Activity of the RAS was suppressed in diabetic 3M mice. We
(37, 47) have previously demonstrated activation of the cardiac
RAS in diabetes, inhibition of which prevents the development
of diabetic cardiomyopathy. To understand the mechanism of
cardiac protection through NF-B inhibition, we measured
changes in components of the RAS in hearts of WT and 3M
mice in response to hyperglycemia. Both AGT and renin
expression were increased in diabetic WT mice compared with
nondiabetic control mice (Fig. 7, A–C). In diabetic 3M mice,
AGT mRNA expression was increased, but protein expression
did not change significantly, likely due to secretion (Fig. 7, E
and F). However, renin expression was significantly reduced in
diabetic 3M mice compared with nondiabetic control mice
(Fig. 7G). Renin protein levels are not presented as we could
not identify (with certainty) a renin band on Western blots, due
to the nonspecificity of commercially available antibodies. The
above-described changes in the expression of RAS genes
resulted in increased ANG II production in the myocardium of
diabetic WT mice but reduced levels in 3M mice compared
with their respective nondiabetic controls (Fig. 7, D, H, and
L–O). WT and 3M samples were analyzed after a time gap,
resulting in a change in experimental conditions (new batch of
reagents). Whether the difference in baseline ANG II staining
intensity between WT and 3M mice was due to interexperi-
mental variation as a result of the time gap is not clear. For
comparison between baseline values of AGT and renin gene
expression, we reanalyzed samples from control WT and 3M
animals together (Fig. 7, I–K). AGT expression was similar,
whereas renin expression was increased about threefold in 3M
mice compared with WT mice.
DISCUSSION
In the present study, we investigated the role of NF-B
canonical signaling in diabetes-induced cardiac dysfunction
using a genetic model of NF-B inactivation. We observed that
lack of NF-B activation protects animals from developing
diabetic cardiomyopathy. We also reported that the mechanism
of protection, by NF-B inhibition, involves an improvement
in Ca2 handling and inhibition of RAS activity in the diabetic
myocardium. We and others (5, 20, 48) have previously de-
scribed that 3M mice are resistant to NF-B activation and
exhibit preserved cardiac structure and function in response to
multiple stimuli. This is the first report to demonstrate cardiac
protection by NF-B inhibition in diabetes using a genetic
approach.
In the heart, activation of NF-B has been reported in
numerous disease contexts, including hypertrophy, ischemia-
Fig. 2. Measurement of diastolic and systolic function by echocardiography. Values are echocardiographic parameters in control and diabetic (STZ) WT and 3M
mice performed on day 0, week 12, and week 24 after the induction of diabetes. A: ratio of mitral valve flow velocities [MV (E/A)]. B: isovolumic relaxation
time (IVRT). C: ejection fraction (EF). D: fractional shortening (FS). Values are expressed as means 
 SE; n  5–7. *P 	 0.05 vs. the respective 0-wk time
point; #P 	 0.05 vs. 0-wk control WT mice.
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reperfusion injury, myocardial infarction, myocarditis, and
diabetes (10, 27). With regard to the STZ model of diabetes,
we observed an increased percentage of p65-positive nuclei in
WT mice treated with STZ after 24 wk, indicating activation of
NF-B signaling (Fig. 4). 3M mice had higher basal levels of
p65-positive nuclei compared with WT mice (statistically non-
significant, P  0.3); however, diabetes did not cause a further
increase in p65-positive nuclei in 3M mice. Although we did
not perform temporal measurements, other investigators have
reported activation of NF-B signaling at different time points
in the myocardium of STZ-treated animals, e.g., in rats at 4 and
12 wk of diabetes by electrophoretic mobility shift assay (19,
22) and increased p65 expression (46); in mice at 8 and 12 wk
by inflammatory cytokine expression (30, 42, 43) and IB-
degradation, p65 expression, and electrophoretic mobility shift
assay (31). To determine the significance of the NF-B signal-
Fig. 3. Measurement of molecular parameters of
cardiac dysfunction. Gene expression of -myosin
heavy chain (MHC; A), -MHC (B), atrial natri-
uretic peptide (ANP; D), and brain natriuretic pep-
tide (BNP; E) was measured by real-time RT-PCR
and normalized to 18S mRNA. C: -MHC-to--
MHC ratio. Values are expressed as fold changes
compared with control 
 SE; n  4–8. *P 	 0.05
and P 	 0.2 vs. respective control mice; #P 
0.05 vs. control WT mice.
Fig. 4. Measurement of p65 nuclear translocation and oxidative stress. A–D: immunostaining of heart sections for p65 to demonstrate nuclear localization, as
a measure of NF-B activity, in control and diabetic (STZ) WT and 3M mice. Green color represents p65, blue represents nuclei, and red represents phalloidin
staining. E: numbers of p65-positive nuclei, indicated by white arrows, were counted (4,000 nuclei from 5–6 images/heart, 4–5 animals/group) and plotted
as percentage of total nuclei. P  0. 06 vs. respective control mice. F–I: oxidative stress was measured by dihydroethidium (DHE) staining (red) of heart
sections. Representative confocal images of DHE staining for WT and 3M mice are shown. J: DHE staining intensity was normalized to section area and plotted.
*P 	 0.05 vs. respective control mice; #P  0.05 vs. control WT mice.
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ing pathway in various cardiac pathological conditions, inves-
tigators have used genetic models that target different members
of this pathway (17, 18, 25, 49). These studies have produced
confounding data, demonstrating both protective and detrimen-
tal functions of NF-B. A broader view has emerged that
suggests that the mechanisms and effects of NF-B activation
are disease and cell type specific. While having a role in the
development of cardiac hypertrophy, this signaling pathway is
also required for preconditioning benefits of myocardial isch-
emia-reperfusion (44).
We observed that STZ-treated 3M mice developed sustained
hyperglycemia similar to WT mice (Fig. 1). Additionally, an
increase in urinary volume and albumin excretion after 24 wk
of diabetes was observed in both WT and 3M mice (Fig. 5),
indicating that cardiac-specific expression of mutated IB-
did not influence systemic parameters, such as hyperglycemia,
and distant organ function, such as diabetic nephropathy.
However, all measures of heart function were completely
preserved in diabetic 3M mice (Fig. 2), suggesting that activa-
tion of the canonical NF-B pathway in the diabetic myocar-
dium is required for cardiac remodeling in this pathological
state. Based on the cardiac morphological data, control 3M
mice appeared hypertrophic compared with control WT mice
(Fig. 1), which was in contrast to the first description of these
animals (5), the reason for which is not clear. Whether this
phenotype of 3M mice contributed to cardiac protection in
diabetes is not known. Whereas WT mice displayed a signif-
icant reduction in systolic and diastolic function after 12 wk of
diabetes, no cardiac dysfunction was observed even after 24
wk in 3M mice. Therefore, inhibition of NF-B activation did
not simply delay the onset of cardiac dysfunction but rather
provided long-term protection, suggesting that this pathway is
a major determinant of cardiac remodeling in diabetes.
Diabetes is considered a condition of chronic inflammation,
which might contribute significantly to cardiac dysfunction.
However, the levels in plasma and expression in tissues of
proinflammatory cytokines have been shown to change with
time in both type 1 and 2 diabetes models (2, 35), making it
difficult to define the inflammatory status and role of individual
cytokines in this disease process. In the heart, although in-
creased early in diabetes, no increase in the expression of
several inflammatory cytokines was observed after 22 wk of
diabetes in STZ-treated rats (2). Similarly, we observed no
increase or decreased expression of IL-1, IL-6, TNF-, and
interferon- in 24-wk diabetic hearts compared with nondia-
betic control hearts (data not shown). Thus, local expression of
inflammatory mediators at this time point did not appear to be
mechanistically linked to cardiac function, corroborating the
above-described rat study (2). To provide a mechanistic expla-
nation for cardiac protection in 3M mice, we investigated local
mechanisms that have a direct role in cardiac function, such as
the cardiac RAS, oxidative stress, and Ca2 handling, which
we hypothesized to be preserved in the absence of NF-B
activation.
Oxidative stress in the diabetic myocardium is widely ac-
cepted as the initiating mechanism that modulates multiple
metabolic and signaling pathways, leading to cardiac dysfunc-
tion and diabetic cardiomyopathy (9, 16). NF-B signaling is a
Fig. 5. Measurement of renal function. Twenty-four-
hour urine collection from WT and 3M was obtained
from mice individually housed in metabolic cages. Uri-
nary volume, albumin, and creatinine levels were deter-
mined. A: urinary volume. B: albumin-to-creatinine ra-
tio. C: albumin excretion. Values are expressed as
means 
 SE; n  3–6. *P 	 0.05 and P  0.07 vs.
respective control mice.
Fig. 6. Measurement of parameters of Ca2 handling in the heart. A and B: protein expression of sarco(endo)plasmic reticulum Ca2-ATPase 2a (SERCA2; A)
and phospholamban (PLB; B) was determined by Western blot analysis in hearts from control and diabetic (STZ) WT and 3M mice. WT and 3M samples were
run on separate blots, with a common sample on all blots to allow for interblot comparison. Intensity of protein bands was quantified by densitometry, normalized
to -actin expression, and plotted as the fold change compared with the control WT sample. C: the ratio of PLB to SERCA2 was plotted separately. D: expression
of ryanodine receptor 2 (Ryr2) was measured by real-time PCR and normalized to 18S mRNA expression. Values are expressed as fold changes compared with
the control WT sample 
 SE; n  4–8. *P 	 0.05 and P  0.1 vs. respective control mice; #P 	 0.05 vs. control WT mice.
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redox-sensitive pathway that enhances inflammation and other
cellular pathways, such as the RAS, which, in turn, may lead to
a further increase in oxidative stress. Consistent with previous
studies, we observed increased ROS in diabetic hearts of WT
mice compared with nondiabetic control hearts (26, 37). In 3M
mice, although baseline oxidative stress was higher than in WT
mice, no further increase was observed in diabetic mice (Fig. 4,
G–L). The reason for the increased basal oxidative stress is not
clear; however, it did not cause any apparent phenotype in 3M
animals, likely due to lack of NF-B activation in these
animals.
Ca2 has multiple roles in the heart, including electrical
activation, excitation-contraction coupling, and regulation of
intracellular signaling (24). An aberration in Ca2 handling by
cardiac myocytes can lead to cardiac hypertrophy and failure.
In diabetic cardiomyopathy, changes in the expression of
regulators of intracellular calcium concentration and cycling,
SERCA2, PLB, and Ryr2, have been associated with decreased
cardiac function (36, 38, 41, 49). Consistent with these find-
ings, we observed a decrease in SERCA2 and Ryr2 expression
in diabetic WT mice, which was completely prevented in 3M
mice (Fig. 6). In another study (49) on the role of NF-B in the
heart after ischemia-reperfusion injury, a complete recovery of
calcium transients was observed in cardiac-specific p65 NF-B
knockout mice, suggesting a role of this transcription factor in
calcium homeostasis. A difference in the basal expression of
Fig. 7. Measurement of renin-angiotensin sys-
tem (RAS) components in the heart. A–H:
hearts from control and diabetic (STZ) WT
(A–D) and 3M (E–H) mice were used to deter-
mine the expression of angiotensinogen (AGT),
renin, and ANG II. AGT expression was deter-
mined by real-time PCR (A and E) and Western
blot analysis (B and F) and normalized to 18S
mRNA or -actin levels, respectively. Renin
expression was determined by real-time PCR (C
and G). I–K: control samples from WT and 3M
mice were analyzed together for baseline com-
parison. Values are expressed as fold changes
compared with control 
 SE; n  4–8. *P 	
0.05 and P 	 0. 1 vs. control mice. L–O:
immunostaining of heart sections for ANG II
(green), WGA (red), and DAPI (blue) from WT
and 3M mice. ANG II staining intensity was
quantified, normalized to tissue area, and plot-
ted for WT (D) and 3M (H) mice. *P	 0.05 vs.
control mice.
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SERCA2 and PLB in p65 knockout mice compared with WT
mice was not observed (49). We also did not find a significant
change in PLB protein levels between control WT and 3M
mice, indicating that this gene was not a direct target of the
NF-B transcriptional program. However, levels of SERCA2
protein were higher by 47%, and Ryr2 expression was lower by
40% in 3M mice compared with control WT mice. More
studies would be required to determine if SERCA2 and Ryr2
transcription are directly regulated by NF-B or not. Previ-
ously, it has been reported that the Ca2 release from intracel-
lular stores through Ryr2 and Ca2/calmodulin-dependent pro-
tein kinase II mediate NF-B activation (21, 41). It is clear
from this study that NF-B, directly or indirectly, also has a
role in maintaining Ca2 homeostasis in the heart, thus pre-
serving cardiac function in diabetes.
Activation of the tissue RAS has a major role in the devel-
opment of diabetes-induced cardiac dysfunction that leads to
diabetic cardiomyopathy. We and others (13, 37, 47) have
shown that inhibition of this system using angiotensin-convert-
ing enzyme inhibitors, angiotensin receptor blockers, or a renin
inhibitor prevents the development of diabetic cardiomyopathy
in experimental animals and retards the progression of cardio-
vascular events in patients. Previously, it has been shown that
NF-B controls the expression of AGT and that ANG II
activates NF-B signaling (1, 6, 14). In addition, angiotensin
receptor blockers and angiotensin-converting enzyme inhibi-
tors have been demonstrated to reduce inflammation through
inhibition of the NF-B pathway (4). Therefore, we investi-
gated whether lack of NF-B activation in 3M mice prevents
diabetes-induced stimulation of the cardiac RAS, thus provid-
ing a mechanism for cardiac protection in these animals.
Surprisingly, in the present study, we did not observe an
attenuation of AGT expression in 3M mice in response to
diabetes (Fig. 7, E and F). This finding suggests that AGT gene
expression by NF-B was mediated by one of the noncanonical
pathways previously described by other investigators in non-
cardiac cells (3, 7, 32). In the latter studies, it was reported that
NF-B signaling regulated AGT expression in a cell type- and
stimulus- dependent manner, either by forming p50:p50 or
p50:p65 dimers or by IB--independent DNA binding of
different p50 isoforms in renal proximal tubular cells, vascular
smooth muscle cells, and hepatocytes, respectively (3, 7, 32).
The formation of p50:p50 homodimers was shown to inhibit
TNF--mediated AGT expression, in contrast to the other two
mechanisms (32). The mechanism of AGT expression by
NF-B has not been studied in the heart. The reason for no
increase in AGT protein levels is not clear, although it is
unlikely due to increased conversion to ANG II, as renin
expression was reduced in these animals (Fig. 7G). It is
possible that we could not capture a change in AGT levels due
to its secretion from the tissue. Importantly, ANG II levels,
which were significantly elevated in diabetic WT mice, were
reduced in diabetic 3M mice, as a result of a decrease in the
expression of renin. The conversion of AGT to ANG I by renin
is the rate-limiting step in ANG II synthesis (29). With regard
to the regulation of renin expression by NF-B, it has been
described only in juxtaglomerular cells, in response to TNF-
stimulation (39, 40). Although an NF-B consensus binding
sequence is present on the mouse renin promoter, it has been
reported that activation of NF-B, by TNF-, reduced renin
gene expression in a juxtaglomerular cell line (As4.1) by an
indirect mechanism. The latter mechanism did not involve p65
binding to the NF-B consensus sequence but rather was
mediated by reduced transactivation capacity of p65 and atten-
uated cAMP-responsive element-binding protein 1 binding to a
cAMP response element on the renin promoter (39). Whether
NF-B is required for basal renin expression is not known.
When we compared AGT and renin expression between WT
and 3M mice, we did not observe a statistically significant
difference in AGT expression, further suggesting that AGT
gene expression is independent of the canonical NF-B path-
way. However, renin expression was increased threefold in 3M
mice compared with WT mice, suggesting that renin was
negatively regulated by the NF-B canonical pathway, consis-
tent with the study discussed above (39). However, hypergly-
cemia reduced renin expression in 3M mice in this study.
These results suggest that NF-B regulates AGT and renin
expression in a gene-specific manner and that these mecha-
nisms may differ in normal and diabetic conditions. However,
it is clear that lack of NF-B activation in diabetic 3M mice
reduced the activity of the cardiac RAS, as evidenced by
reduced ANG II levels, which likely contributed significantly
to the cardiac protective mechanism in diabetic 3M mice.
Significance. Cardiovascular diseases are a major cause of
morbidity and mortality in the diabetic population. Several
mechanisms, including oxidative stress, inflammation, im-
paired Ca2 homeostasis, and activation of the RAS, have a
major role in the development of diabetes-induced cardiac
dysfunction that leads to the specific condition referred to as
diabetic cardiomyopathy. A unifying molecular mechanism
that would explain the development of the above pathological
markers is lacking. NF-B is a pleiotropic transcription factor
that not only is activated by oxidative stress, intracellular Ca2
Fig. 8. Schematic representation of the putative cross-talk between NF-B,
oxidative stress, intracellular Ca2, and the RAS in cardiac myocytes
exposed to hyperglycemia. Hyperglycemia increases oxidative stress as a
byproduct of glucose metabolism and intracellular Ca2 levels through
intermediates of the glycolytic pathway. Oxidative stress and intracellular
Ca2 have been shown to activate NF-B signaling. NF-B controls the
transcription of genes of RAS components, enzymes that modulate oxida-
tive stress (e.g., NADPH oxidase), and Ca2-handling proteins. ANG II,
the bioactive peptide of the RAS, in turn increases oxidative stress and
intracellular Ca2 levels and activates NF-B signaling. Thus, NF-B
appears to be the nodal point for the convergence of major cellular events
that contribute to cardiac dysfunction in diabetes. This study provides
evidence that lack of NF-B activation prevents diabetic cardiomyopathy.
GAD-3P, glyceraldehyde 3-phosphate; DAG, diacylglycerol; TCA cycle,
tricarbocylic acid cycle; AT1, ANG II type 1 receptor; ACE, angiotensin-
converting enzyme; [Ca2]i, intracellular Ca2 concentration.
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release, and ANG II but also controls these events in a
continuous feedback manner. Figure 8 shows a putative posi-
tion of NF-B in the cellular mechanism of diabetic cardio-
myopathy that needs further investigation. This study provides
evidence of NF-B as a focal point of major pathological
changes in the diabetic myocardium and might provide an
attractive therapeutic target.
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